About Double Point Ventures
Double Point Ventures is a venture capital firm located in Boston, United States. As of Apr 2026, Double Point Ventures is an active investor, having invested in 7 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Healthcare. Most recently it participated in the $***** Series A round of Lighthouse Pharma A lot of funds co-invest with Double Point Ventures, with names like Bioluminescence Ventures sharing a substantial percentage of its portfolio. Double Point Ventures has team of 3 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 3 more
Portfolio Soonicorns
Deals in last 12 months
Double Point Ventures' List of Top Investments
Double Point Ventures has a portfolio of 7 companies. Their most notable investments are in Synchron and GEMMA Biotherapeutics.Their portfolio spans across United States and Switzerland. They have invested in Life Sciences, High Tech, Healthcare, across Series B, Series C and 3 more. Here is the list of top investments by Double Point Ventures:
1. Synchron
Developer of implantable bioelectronics for the treatment of neurological conditions. The company offers a motor neuroprosthesis the Stentrode which helps paralyzed patients regain the ability to communicate. Also, provides endovascular neuromodulation minimally invasive device that stimulates brain or nerve activity for the treatment of Parkinson’s disease, epilepsy, depression, and others.
Key facts about Synchron
- Founded Year: 2016
- Location: Brooklyn (United States)
- Stage: Series D
- Total Funding till date: $345M
- Employee Count: 126 as on Mar 31, 2026
- Investors: Qatar Investment Authority, Bezos Expeditions and 32 Others
- Latest Funding Round: Series D, Nov 06, 2025, $*****
- Highlight: Editors' Pick
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
Key facts about Umoja Biopharma
- Founded Year: 2019
- Location: Seattle (United States)
- Stage: Series C
- Total Funding till date: $363M
- Employee Count: 226 as on Apr 30, 2026
- Investors: RTW Investments, Temasek and 15 Others
- Latest Funding Round: Series C, Jan 14, 2025, $*****
- Highlight: Editors' Pick
3. Cerevance
Cerevance is focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company has licensed technology created in the Howard Hughes Medical Institute (HHMI) laboratory of Nathaniel Heintz at the Rockefeller University. Dr. Heintz’s laboratory work involves identifying genes, circuits, cells, and proteins that contribute to the function of the mammalian brain and to its dysfunction in neurological diseases.
Key facts about Cerevance
- Founded Year: 2015
- Location: Cambridge (United States)
- Annual Revenue: £0 - £1M as on Dec 31, 2024
- Stage: Series B
- Total Funding till date: $204M
- Employee Count: 37 as on Apr 30, 2026
- Investors: Foresite Capital, Takeda and 15 Others
- Latest Funding Round: Series B, Apr 26, 2024, $*****
- Highlight: Editors' Pick
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells
Key facts about ImmunOs Therapeutics
- Founded Year: 2013
- Location: Schlieren (Switzerland)
- Stage: Series C
- Total Funding till date: $102M
- Employee Count: 12 as on Apr 30, 2026
- Investors: Samsara BioCapital, Pfizer and 15 Others
- Latest Funding Round: Series C, Sep 17, 2024, $*****
- Highlight: Editors' Pick
5. DermBiont
Developer of microbial therapeutics designed to treat skin diseases. The topical therapeutic candidates include DBI-001 for eczema, athlete's foot, and nail fungus, DBI-002 for inflammatory dandruff, and SM-020 for benign skin tumors.
Key facts about DermBiont
- Founded Year: 2015
- Location: Melrose (United States)
- Stage: Series B
- Total Funding till date: $78.9M
- Employee Count: 14 as on Apr 30, 2026
- Investors: Toba Capital, Viking Global Investors and 15 Others
- Latest Funding Round: Series B, Oct 04, 2023, $*****
- Highlight: Editors' Pick
Double Point Ventures' Year-on-Year Investment Trends
Double Point Ventures has invested in 7 companies over the last 3 years, with an average of 2 new investments annually in the last 3 years. In 2025, it made 2 investments, while as of Apr 2026, it has made 1 investment in this year. Its most recent first time investment was in Lighthouse Pharma.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 2 | 0 | 2 |
2024 | 3 | 0 | 3 |
2023 | 1 | 0 | 1 |
Double Point Ventures' Investments by Stage
Double Point Ventures has made 2 investments in Series B stage with an average round size of $39.8M, 2 investments in Series C stage with an average round size of $55.5M, 1 investment in Seed stage with an average round size of $34M, 1 investment in Series A stage with an average round size of $15.2M and 1 investment in Series D stage with an average round size of $200M.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Series C | 2 |
Seed | 1 |
Series A | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Double Point Ventures' Investments by Sector
Double Point Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare and Sustainability Tech. Notably, it has invested in 6 Enterprise (B2B) companies, 6 Tech companies and 1 Tech hardware company.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
High Tech | 2 |
Healthcare | 1 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Double Point Ventures' Investments by Geography
Double Point Ventures has made most investments in United States (6), followed by Switzerland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 6 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
Double Point Ventures' recent investments
Double Point Ventures has made 1 investments in 2026 so far - Lighthouse Pharma.Here are the most recent investments by Double Point Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 22, 2026 | United States | Series A | 8551 | - | |
Nov 06, 2025 | United States | Series D | 4696 | [+10] | |
Jan 14, 2025 | United States | Series C | 4963 | [+10] | |
Dec 23, 2024 | United States | Seed | 5012 | ||
Sep 17, 2024 | Switzerland | Series C | 9206 | [+3] |
Team profile of Double Point Ventures
Double Point Ventures has a team of 3 members including 2 Partners located in United States. Double Point Ventures' team does not sit on the board of any company as of now.Co-investors of Double Point Ventures
Over the past 3 years, 83 investors have co-invested in Double Point Ventures's portfolio companies. This includes funds and angels.
- Invested before Double Point Ventures: Gates Frontier, Casdin Capital and 65 others have invested in rounds before Double Point Ventures. There are 2 companies where Gates Frontier has invested before Double Point Ventures and 2 companies where Casdin Capital has invested before Double Point Ventures.
- Top Co-investors of Double Point Ventures: 16 investors entered a company along with Double Point Ventures. These include investors like Bioluminescence Ventures (2 companies).
Recent News related to Double Point Ventures
•
•
Synchron Raises $200 Million Series D to Advance Brain-Computer Interface TechnologyBusiness Wire•Nov 06, 2025•Synchron, National Reconstruction Fund, Double Point Ventures, T.Rx Capital and 9 others
•
•
Umoja secures $100m to advance CAR-T cell therapy pipelinePharmaceutical Technology•Jan 15, 2025•Umoja Biopharma, Double Point Ventures, DCVC, ARK Investment Management and 3 others
•
Seattle immunotherapy startup Umoja Biopharma raises $100MGeekWire•Jan 14, 2025•, Double Point Ventures, , Cormorant Asset Management and 12 others
•
Umoja’s $100M Series C will advance its bid for more convenient cell therapiesEndPoints News•Jan 14, 2025•Umoja Biopharma, Double Point Ventures, DCVC, Fenwick & West
•
GEMMABio Secures $34 Million in Seed Funding to Drive Gene Therapy Advancementsintelligence360•Jan 09, 2025•GEMMA Biotherapeutics, Double Point Ventures, Bioluminescence Ventures, Earlybird and 1 other
•
GEMMA Biotherapeutics lands $34m seedVCJ•Dec 23, 2024•GEMMA Biotherapeutics, Double Point Ventures, Bioluminescence Ventures, Earlybird and 1 other
•
•
The M&A Class Action Firm Continues to Investigate the Mergers of OB, LUMO, PIK and PORTBenzinga•Nov 16, 2024•Monteverde, Outbrain, Teads, Lumos Pharma and 5 others
